Chronic Wounds Market

Market Overview:

The 7 major chronic wounds markets reached a value of US$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 7.6 Billion by 2034, exhibiting a growth rate (CAGR) of 2.96% during 2024-2034.

The chronic wounds market has been comprehensively analyzed in IMARC's new report titled "Chronic Wounds Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic wounds are injured tissues that do not follow the normal healing process and fail to heal within the expected timeframe. This condition typically persists for an extended period, often exceeding three months, and may show limited or no improvement over time. The symptoms of the ailment can vary in patients depending on the underlying cause and the specific type of wound. Some common indications of this illness include ongoing pain or discomfort at the affected site, swelling, redness, warmth, an unpleasant odor, the appearance of red, spongy, or excessively raised tissue, darkened skin, etc. In many cases, individuals suffering from the disease may also experience fever, itchiness, leakage of milky pus, bleeding, poor sleep quality, etc. The diagnosis of chronic wounds typically involves a comprehensive assessment of underlying symptoms, a medical history, and a physical examination. Numerous laboratory tests may be ordered to determine blood circulation, check for signs of infection, measure blood glucose levels, or evaluate nutritional deficiencies that can contribute to the delayed healing process. Additionally, the healthcare provider may further perform a tissue biopsy to confirm the diagnosis.

The increasing cases of peripheral artery disease and diabetes, which can damage blood vessels and impair circulation, leading to delayed tissue healing, are primarily driving the chronic wounds market. In addition to this, the rising incidence of autoimmune disorders that affect immune functions and disrupt the body's normal physiological processes is creating a positive outlook for the market. Moreover, the widespread adoption of biological dressings, such as skin substitutes or grafts derived from human or animal sources, since they aid in wound healing by providing a favorable environment for tissue regeneration, is further bolstering the market growth. Apart from this, the inflating application of topical corticosteroids, including hydrocortisone, betamethasone dipropionate, triamcinolone, etc., to provide symptomatic relief and reduce inflammation, itching, or irritation in the affected area, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of pulsed electromagnetic field (PEMF) therapy for the treatment of the condition, since it increases blood flow and enhances cellular activity, is expected to drive the chronic wounds market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the chronic wounds market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic wounds and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic wounds market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic wounds market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic wounds market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic wounds marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic wounds market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic wounds market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic wounds market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of chronic wounds across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic wounds by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic wounds by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of chronic wounds by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with chronic wounds across the seven major markets?
• What is the size of the chronic wounds patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic wounds?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Wounds: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic wounds drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic wounds market?
• What are the key regulatory events related to the chronic wounds market?
• What is the structure of clinical trial landscape by status related to the chronic wounds market?
• What is the structure of clinical trial landscape by phase related to the chronic wounds market?
• What is the structure of clinical trial landscape by route of administration related to the chronic wounds market?